Advertisement

Topics

Innoviva Completes Refinancing of its 9% 2029 Non-Recourse Notes

07:00 EDT 21 Aug 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Closes $250 Million Term B Loan Refinancing plan expected to reduce the associated current cash interest expense by nearly one-half Innoviva, Inc. (“Innoviva” or the “Company”) (NASDAQ: INVA) today an...

Other Sources for this Article

Innoviva, Inc.
Eric d’Esparbes, 650-238-9640
Senior Vice President and Chief Financial Officer
investor.relations@inva.com

NEXT ARTICLE

More From BioPortfolio on "Innoviva Completes Refinancing of its 9% 2029 Non-Recourse Notes"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...